When was Aurion Biotech founded?

Aurion Biotech was founded in 2021 and raised its 1st funding round 1 year after it was founded.

Where is Aurion Biotech located?

Aurion Biotech is headquartered in Seattle, United States.

How many employees does Aurion Biotech have?

As of Jul 31, 2026, the latest employee count at Aurion Biotech is 113.

Is Aurion Biotech a funded company?

Aurion Biotech is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Apr 12, 2022.

When was the latest funding round of Aurion Biotech?

Aurion Biotech's latest funding was a $***** Series C round on Apr 12, 2022, with participation from 7 investors.

Where does Aurion Biotech rank among its competitors?

Aurion Biotech ranks 5th amongst 59 active competitors, of which 16 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Claris Bio, which secured $118M in Jul, 2026.

Who are the top competitors of Aurion Biotech?

Aurion Biotech's top competitors include Neurona Therapeutics, Vericel Corporation and Gamida Cell. Among them, Claris Bio secured the most recent funding round in July, 2026.

Aurion Biotech - 2026 Company Profile, Team, Funding & Competitors

Aurion Biotech is an acquired company based in Seattle (United States), founded in 2021. It operates as a Developer of regenerative cell therapies for ocular diseases. Aurion Biotech has raised $120M in funding from Deerfield. The company has 59 active competitors, including 16 funded and 25 that have exited. Its top competitors include companies like Neurona Therapeutics, Vericel Corporation and Gamida Cell.

Company Details

Developer of regenerative cell therapies for ocular diseases. The lead candidate Vyznova is for the treatment of corneal endothelial disease. The company collects healthy cells from a donor cornea which is propagated and used for the treatment.

Website: aurionbiotech.com
Email ID: *****@aurionbiotech.com

Key Metrics

Founded Year

2021

Location

Seattle, United States

Stage

Acquired

Total Funding

$120M in 1 round

Latest Funding Round

Series C, Apr 12, 2022, $*****

Investors

Deerfield & 6 more

Ranked

5^th among 59 active competitors

Employee Count

113 as on Jul 31, 2026

Similar Companies

Neurona Therapeutics & 78 more

Exit Details

Acquired by Alcon (Mar 26, 2025)

View Aurion Biotech's full profile

Aurion Biotech got acquired by Alcon on Mar 26, 2025.

Click here to take a look at Aurion Biotech's acquisition in detail

Aurion Biotech has raised a total funding of $120M over 1 round. Its latest funding round was a Series C round on Apr 12, 2022 for $*****. 7 investors participated in its latest round. Aurion Biotech has 7 institutional investors.

Here is the list of recent funding rounds of Aurion Biotech:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 12, 2022	4232722	Series C	1002051	2113323	1679458	3976457

Access funding benchmarks and valuations. Sign up today!

View details of Aurion Biotech's funding rounds and investors

Aurion Biotech's employee count trend

Aurion Biotech has 113 employees as of Jul 26. Here is Aurion Biotech's employee count trend over the years:

Uncover Aurion Biotech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Aurion Biotech include Neurona Therapeutics, Vericel Corporation and Gamida Cell. Here is the list of Top 10 competitors of Aurion Biotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Neurona Therapeutics 2008, San Francisco (United States), Acquired	Developer of cell-based therapies to treat intractable neurological diseases	$418M	The Column Group, Cormorant Asset Management ... & 15 others	62/100
2nd	Vericel Corporation 1989, Cambridge (United States), Public	Developer of autologous stem cell therapies	$40M	Eastern Capital, Ignite 500 & 2 others	62/100
3rd	Gamida Cell 1998, Jerusalem (Israel), Public	Developer of cell therapies to treat cancer and other serious diseases	$139M	Shavit Capital, Auriga Partners & 14 others	61/100
4th	Claris Bio 2018, Jersey City (United States), Series B	Developer of a topical formulation for the treatment of corneal wounds, ulcers, and scars	$175M	Samsara BioCapital, Catalio Capital Management ... & 11 others	59/100
5th	Aurion Biotech 2021, Seattle (United States), Acquired	Developer of regenerative cell therapies for ocular diseases	$120M	Deerfield, Petrichor & 5 others	58/100
6th	ViaCyte 1999, San Diego (United States), Acquired	Developer of cell therapy for the treatment of diabetes	$389M	Bain Capital Life Sciences, Sanderling Ventures ... & 21 others	54/100
7th	Novadip 2013, Mont Saint Guibert (Belgium), Series B	Developer of stem cell-based therapies for bone healing disorders and bone defects	$77M	New Science Ventures, Fund+ & 14 others	53/100
8th	CellProthera 2008, Mulhouse (France), Series B	Developer of cell-based therapies for regenerative medicine, specifically cardiac repair	$31.3M	SODIV, Bpifrance & 3 others	53/100
9th	Capricor Therapeutics 2005, Los Angeles (United States), Public	Developer of regenerative medicine for cardiovascular disorders	-	Two River, Mayo Clinic Ventures & 3 others	53/100
10th	Epibone 2013, Brooklyn (United States), Series B	Developer of patient‑specific bone and cartilage grafts	$48.6M	Kendall Capital Partners, MBX Capital & 25 others	51/100